• Sionna Therapeutics director Peter A. Thompson reported the sale of 101 shares of common stock on May 27, 2026.
• Shares were sold at USD 44.49, leaving 2,671,721 shares beneficially owned indirectly.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sionna Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000947871-26-000588), on May 29, 2026, and is solely responsible for the information contained therein.